The Manche press - alert against Androcur and its generics
Health mobilization against hormonal treatment increasing the risk of tumor.
The active molecule of this hormonal treatment sold under the name of Androcur or its equivalents is cyproterone acetate. As the ANSM confirms, it increases the risk of meningioma "according to the duration of use and the dosage".
Cyproterone acetate has multiplied by seven, after six months, and twenty, after five years, the risk of developing meningioma.
An effect which, as early as 2009, imposed to include this risk in the notice of the drug from 2011. And yet ... “We continued to prescribe this medication to us when doctors knew the risk of meningioma. The health insurance fund speaks of 500 cases, a low figure since many women have developed a meningioma san ssavoir that it is linked to Androcur" accuses Emmanuel Mignation. […]
Find the other Amavea articles here
